Further to this, the work described herein details specifically the action of an active GLP-1 analogue, and also extrapolates the utility of such therapies in the management of the atherogenic dyslipidaemia associated with obesity and diabetes. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.